{
    "id": 5725,
    "fullName": "PDGFRB over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "PDGFRB over exp indicates an over expression of the Pdgfrb protein. However, the mechanism causing the over expression is unknown.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 5159,
        "geneSymbol": "PDGFRB",
        "terms": [
            "PDGFRB",
            "CD140B",
            "IBGC4",
            "IMF1",
            "JTK12",
            "KOGS",
            "PDGFR",
            "PDGFR-1",
            "PDGFR1",
            "PENTT"
        ]
    },
    "variant": "over exp",
    "createDate": "05/04/2015",
    "updateDate": "11/29/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2277,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with XL888 increased apoptosis and decreased growth of Zelboraf (vemurafenib)-resistant human melanoma cell lines harboring a BRAF V600E mutation and over expression of PDGFRB in cell culture and in xenograft models (PMID: 22351686).",
            "molecularProfile": {
                "id": 6908,
                "profileName": "BRAF V600E PDGFRB over exp"
            },
            "therapy": {
                "id": 970,
                "therapyName": "XL888",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2956,
                    "pubMedId": 22351686,
                    "title": "The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22351686"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2278,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, over expression of PDGFRB conferred acquired resistance to Zelboraf (vemurafenib) in melanoma cells harboring BRAF V600E in culture (PMID: 21107323).",
            "molecularProfile": {
                "id": 6908,
                "profileName": "BRAF V600E PDGFRB over exp"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2959,
                    "pubMedId": 21107323,
                    "title": "Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21107323"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7834,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with BI-847325 inhibited growth of a BRAF-mutant melanoma cell line with BRAF-inhibitor resistance due to PDGFRB over expression in culture (PMID: 25873592).",
            "molecularProfile": {
                "id": 26063,
                "profileName": "BRAF mut PDGFRB over exp"
            },
            "therapy": {
                "id": 1059,
                "therapyName": "BI-847325",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6506,
                    "pubMedId": 25873592,
                    "title": "The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25873592"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14972,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Gleevec (imatinib mesylate) treatment demonstrated no clinical activity, resulted in no objective response (0/13) in patients with metastatic breast cancer demonstrating Pdgfrb overexpression and negative Kit expression (PMID: 18515258).",
            "molecularProfile": {
                "id": 30418,
                "profileName": "KIT neg PDGFRB over exp"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 11879,
                    "pubMedId": 18515258,
                    "title": "Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18515258"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 5558,
            "profileName": "PDGFRB over exp",
            "profileTreatmentApproaches": [
                {
                    "id": 4351,
                    "name": "PDGFR Inhibitor (Pan)",
                    "profileName": "PDGFRB over exp"
                },
                {
                    "id": 4352,
                    "name": "PDGFR-beta Inhibitor",
                    "profileName": "PDGFRB over exp"
                }
            ]
        },
        {
            "id": 6908,
            "profileName": "BRAF V600E PDGFRB over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26063,
            "profileName": "BRAF mut PDGFRB over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30418,
            "profileName": "KIT neg PDGFRB over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}